SARAH HART: Open Payments
NPI 1013339522 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,294 in 59 payments from 9 companies in 2025. Trend: 2023 $592 · 2024 $734 · 2025 $1,294
Food & beverage: $1,294
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 16 | $538 |
| Gilead Sciences, Inc. | 15 | $277 |
| Ipsen Biopharmaceuticals, Inc | 10 | $171 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $151 |
| Intercept Pharmaceuticals, Inc. | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Eton Pharmaceuticals, Inc. | 1 | $24 |
| Boston Scientific Corporation | 1 | $23 |
| ABBVIE INC. | 1 | $16 |
Products named: REZDIFFRA, IQIRVO, XIFAXAN, OCALIVA, LIVTENCITY, ALKINDI, WATCHMAN, MAVYRET.
Industry payments across OK — which companies pay providers there.
